Wrapping up its ninth year, CHI’s Immunogenicity and Bioassay Summit was host to industry, academia and regulatory authorities who shared new ways of overcoming immunogenicity and bioassay challenges at 3 co-located conferences,
4 short courses, 2 training seminars and the Bioassays for Immuno-Oncology symposium. Cambridge Healthtech Institute (CHI) would like to thank all the speakers, attendees, sponsors, and exhibitors for their participation. The 2017
- 300 Delegates from 165 Companies
- 75 Scientific Presentations & Case Studies, including FDA
- 25 Poster Presentations
- 20 Countries Represented
- 16 Exhibitors
View the 2017 Attendee List
If you missed our 2017 event, you can reserve a copy of the conference proceedings CD to access the speakers’ slides and poster abstracts
our delegates received on-site.
2017 Keynote & Featured Speakers
Viswanath Devanarayan, Ph.D.
Adjunct Professor, University of Illinois at Chicago
Executive Director and Head, Global Statistics, Charles River Labs
Susan Kirshner, Ph.D.
Associate Chief, Immunology Lab, Therapeutic Proteins, Biotechnology
Thomas Little, Ph.D.
President, Bioassay Sciences
Thomas A. Little Consulting
Chief Technology Officer
Joao Pedras-Vasconcelos, Ph.D.
Biotech Quality and Immunogenicity Reviewer, Biotechnology Products
Amy S. Rosenberg, M.D.
Division Director, Office of Biotechnology Products
Senior Statistician, Non-Clinical Statistics
“This conference provides very deep and broad scientific presentations, roundtable discussions, and excellent networking opportunities for scientists, managers/directors, CROs, vendors and consultants.”
Senior Group Leader, Pfizer
“The Immunogenicity and Bioassay Summit covers up-to-date research and regulatory advances on all aspects of immunogenicity. It’s a very good meeting for experts and newcomers to the field.”
Director, Head, Bioanalytical and Biomarker Development, Research & Nonclinical Development, Shire
“Program and participants first class.”
- Associate Director, Novo Nordisk
“Great to get regulatory perspectives on challenges and expectations. The higher level strategic discussions were very informative.”
- Beth Arnold, Director, Biologics & Vaccine Bioanalytics, Merck
“Breakout interaction with FDA experts was very valuable.”
- Associate Director, Alexion Pharmaceuticals Inc.
View more testimonials